Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 10, 2013, Pages 5067-5079

  Lade, Julie M ^a   Avery, Lindsay B ^a   Bumpus, Namandjé N ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; COMPLEMENTARY DNA; CYTOCHROME P450; DRUG METABOLITE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; HOMOCYSTEINE; RILPIVIRINE; TYROSINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; METABOLOMICS; NONHUMAN; OXYGENATION; PRIORITY JOURNAL; SPECTROSCOPY; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; CHROMATOGRAPHY, LIQUID; CRICETINAE; DOGS; GUINEA PIGS; HUMANS; MICE; MICROSOMES, LIVER; NITRILES; PYRIMIDINES; RABBITS; RATS; TANDEM MASS SPECTROMETRY;

EID: 84884219872     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01401-13     Document Type: Article

References (30)

1. Wainberg MA. 2013. Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir. HIV AIDS (Auckl.) 5:41-49.
2. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Bethune MP. 2004. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitorresistant human immunodeficiency virus type Antimicrob. Agents Chemother. 48:4680-4686.
3. Janssen PA, Lewi PJ, Arnold E, Daeyaert F, de Jonge M, Heeres J, Koymans L, Vinkers M, Guillemont J, Pasquier E, Kukla M, Ludovici D, Andries K, de Bethune MP, Pauwels R, Das K, Clark AD Jr, Frenkel YV, Hughes SH, Medaer B, De Knaep F, Bohets H, De Clerck F, Lampo A, Williams P, Stoffels P. 2005. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile (R278474, rilpivirine). J. Med. Chem. 48:1901-1909.
4. Abraham BK, Gulick R. 2012. Next-generation oral preexposure prophylaxis: beyond tenofovir. Curr. Opin. HIV AIDS 7:600-606.
5. Baert L, van 't Klooster G, Dries W, Francois M, Wouters A, Basstanie E, Iterbeke K, Stappers F, Stevens P, Schueller L, Van Remoortere P, Kraus G, Wigerinck P, Rosier J. 2009. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur. J. Pharm. Biopharm. 72:502-508.
6. Cohen CJ, Andrade-Villanueva J, Clotet B, Fourie J, Johnson MA, Ruxrungtham K, Wu H, Zorrilla C, Crauwels H, Rimsky LT, Vanveggel S, Boven K. 2011. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, noninferiority trial. Lancet 378:229-237.
7. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K. 2011. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 378:238-246.
8. Bumpus NN. 2011. Efavirenz and 8-hydroxyefavirenz induce cell death via a JNK and BimEL-dependent mechanism in primary human hepatocytes. Toxicol. Appl. Pharmacol. 257:227-234.
9. Tovar-y-Romo LB, Bumpus NN, Pomerantz D, Avery LB, Sacktor N, McArthur JC, Haughey NJ. 2012. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J. Pharmacol. Exp. Ther. 343:696-703.
10. Tibotec Pharmaceuticals. 2011. Edurant (rilpivirine) tablets full prescribing information. Tibotec Pharmaceuticals, County Cork, Ireland.
11. Gilead Sciences Inc.2011. Complera highlights of prescribing information. Gilead Sciences Inc., Foster City, CA.
12. Suzuki H, Kneller MB, Haining RL, Trager WF, Rettie AE. 2002. N-3-Benzyl-nirvanol and N-3-benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19. Drug Metab. Dispos. 30:235-239.
13. Walsky RL, Obach RS. 2007. A comparison of 2-phenyl-2-(1- piperidinyl)propane (ppp), 1,1=,1-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6. Drug Metab. Dispos. 35:2053-2059.
14. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. 2003. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306:287-300.
15. Ingelman-Sundberg M, Sim SC. 2010. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Biochem. Biophys. Res. Commun. 396:90-94.
16. Sharma D, Lau AJ, Sherman MA, Chang TK. 2013. Agonism of human pregnane X receptor by rilpivirine and etravirine: comparison with first generation non-nucleoside reverse transcriptase inhibitors. Biochem. Pharmacol. 85:1700-1711.
17. Yanakakis LJ, Bumpus NN. 2012. Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolism. Drug Metab. Dispos. 40:803-814.
18. Weiss J, Haefeli WE. 2013. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drugmetabolising enzymes in vitro. Int. J. Antimicrob. Agents 41:484-487.
19. Ohno S, Nakajin S. 2009. Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 37:32-40
20. Lachau-Durand S, Mamidi RNVS, Cuyckens F, Michlova V, Mannens G, Raoof A. 2009. Absorption, metabolism and excretion of TMC278, an NNRTI, after a single oral dose of 150mg in healthy male volunteers. HIV Med. 10(Suppl 2):93.
21. Fairman DA, Collins C, Chapple S. 2007. Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? Drug Metab. Dispos. 35:2159-2165.
22. Willson TM, Kliewer SA. 2002. PXR, CAR and drug metabolism. Nat. Rev. Drug Discov. 1:259-266.
23. Moore LB, Maglich JM, McKee DD, Wisely B, Willson TM, Kliewer SA, Lambert MH, Moore JT. 2002. Pregnane X receptor (PXR), constitutive androstane receptor (CAR), and benzoate X receptor (BXR) define three pharmacologically distinct classes of nuclear receptors. Mol. Endocrinol. 16:977-986.
24. Gardner-Stephen D, Heydel JM, Goyal A, Lu Y, Xie W, Lindblom T, Mackenzie P, Radominska-Pandya A. 2004. Human PXR variants and their differential effects on the regulation of human UDPglucuronosyltransferase gene expression. Drug Metab. Dispos. 32:340- 347.
25. Tukey RH, Strassburg CP. 2000. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40: 581-616.
26. Hufton SE, Jennings IG, Cotton RG. 1995. Structure and function of the aromatic amino acid hydroxylases. Biochem. J. 311(Part 2):353-366.
27. Williams KT, Schalinske KL. 2010. Homocysteine metabolism and its relation to health and disease. Biofactors 36:19-24.
28. Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D. 2012. Asymmetric dimethylarginine concentrations decrease in patients with HIV infection under antiretroviral therapy. Antivir. Ther. 17:1021-1027.
29. Haines RJ, Pendleton LC, Eichler DC. 2011. Argininosuccinate synthase: at the center of arginine metabolism. Int. J. Biochem. Mol. Biol. 2:8-23.
30. Resino S, Sanchez-Conde M, Berenguer J. 2012. Coinfection by human immunodeficiency virus and hepatitis C virus: noninvasive assessment and staging of fibrosis. Curr. Opin. Infect. Dis. 25:564-569.